Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | F2 | P00734 | 1/20 | 0.72 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160969 | 1.00 | F10 (0.76) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18897606 | 1.00 | F10 (0.76) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1160964 | 0.90 | MAOB (0.62) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78345 | 0.86 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19230362 | 0.86 | F10 (0.87) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806189 | 0.86 | F10 (0.87) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78508 | 0.86 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15326026 | 0.85 | F10 (0.81) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL806187 | 0.85 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18897718 | 0.84 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459555-B1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA D D NOVO MESTO (SI) | 2021-11-03 | — | — | EP | disclosed |
| US-9663505-B2 | Process for the preparation of rivaroxaban | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-05-30 | — | — | US | disclosed |
| US-9663505-B2 | Process for the preparation of rivaroxaban | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-05-30 | — | — | US | disclosed |
| US-20150011756-A1 | PROCESS FOR PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | MEGAFINE PHARMA P LTD (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011756-A1 | PROCESS FOR PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | MEGAFINE PHARMA P LTD (IN) | 2015-01-08 | — | — | US | disclosed |
| WO-2014155259-A2 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-10-02 | — | — | WO | disclosed |
| EP-2459555-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., Novo Mesto (SI) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011756-A1 | PROCESS FOR PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, TFPI | F10 27/4885CYP1A2 16/4885CYP3A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.